Advertisement
AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schackman, B. R.
Right arrow Articles by Freedberg, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schackman, B. R.
Right arrow Articles by Freedberg, K. A.
Related Collections
Right arrow Health Care Facilities/Services
Right arrow Insurance
Right arrow Other Health Financing
Right arrow HIV/AIDS
Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults

Bruce R. Schackman, PhD, Sue J. Goldie, MD, MPH, Milton C. Weinstein, PhD, Elena Losina, PhD, Hong Zhang, SM and Kenneth A. Freedberg, MD, MSc

At the time of the study Bruce R. Schackman was, and Sue J. Goldie, Milton C. Weinstein, and Kenneth A. Freedberg are now, with the Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass. Elena Losina and Dr. Freedberg are with the Department of Epidemiology and Biostatistics, Boston University School of Public Health, Boston. Dr. Losina, Hong Zhang, and Dr. Freedberg are with the Division of General Medicine and Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston.


Figure 1
Figure 1
Figure 1
View larger version (38K):

[in a new window]
  		FIGURE 1—— Clinical outcomes of early vs deferred antiretroviral therapy (ART) for HIV-infected adults with CD4 cell counts of 500/µL at cohort entry. (A) Mean CD4 cells/µL of patients remaining alive. (B) Cumulative deaths per 1000 patients. (C) Cumulative opportunistic infections per 1000 patients.

 

Figure 2
View larger version (19K):

[in a new window]
  		FIGURE 2—— Budget impact on all government payers of early vs deferred antiretroviral therapy (ART) strategies: undiscounted 1998 dollars per patient with CD4 cell count of 500/µL at cohort entry.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Public Health Association